Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EB-3D 是一种选择性胆碱激酶 α 抑制剂,对 ChoKα1 的IC50值为 1 μM。它影响 ChoKα 表达、AMPK 激活、细胞凋亡、内质网应激和脂质代谢,具有抗癌活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 658 | 现货 | ||
2 mg | ¥ 968 | 现货 | ||
5 mg | ¥ 1,580 | 现货 | ||
10 mg | ¥ 2,490 | 现货 | ||
25 mg | ¥ 4,260 | 现货 | ||
50 mg | ¥ 6,070 | 现货 | ||
100 mg | ¥ 8,370 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,230 | 现货 |
产品描述 | EB-3D is a potent and selective choline kinase alpha 1 (ChoKα1) inhibitor(IC50 : 1 μM).with anti-cancer activity. |
靶点活性 | ChoKα1:1 μM |
体外活性 | EB-3D?exhibits a potent antiproliferative activity in a panel of T-leukemia cell lines and primary cultures of pediatric patients.?Moreover, the drug strongly induces apoptosis and more importantly it enhanced T-leukemia cell sensitivity to chemotherapeutic agents, such as dexamethasone and l-asparaginase.?In addition, the compound induces an early activation of AMPK, the main regulator of cellular energy homeostasis, by its phosphorylation at residue T712 of catalytic subunit α, and thus repressing mTORC1 pathway, as shown by mTOR S2448 dephosphorylation.?The inhibition of mTOR in turn affects the activity of several known downstream targets, such as 4E-BP1, p70S6K, S6 Ribosomal Protein and GSK3 that ultimately may lead to a reduction of protein synthesis and cell death[1]. |
细胞实验 | Cell Line:JURKAT, CCRF-CEM, HSB-2, MOLT-16, DNA-41, LOUCY, PEER, ALL-SIL cells. Concentration:0.001, 0.01, 0.1, 1, 10, 100 μM.Incubation Time:72 hours |
分子量 | 644.4 |
分子式 | C30H36Br2N4O2 |
CAS No. | 1839150-63-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (77.59 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.5518 mL | 7.7592 mL | 15.5183 mL | 38.7958 mL |
5 mM | 0.3104 mL | 1.5518 mL | 3.1037 mL | 7.7592 mL | |
10 mM | 0.1552 mL | 0.7759 mL | 1.5518 mL | 3.8796 mL | |
20 mM | 0.0776 mL | 0.388 mL | 0.7759 mL | 1.9398 mL | |
50 mM | 0.031 mL | 0.1552 mL | 0.3104 mL | 0.7759 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
EB-3D 1839150-63-8 Apoptosis Chromatin/Epigenetic Neuroscience PI3K/Akt/mTOR signaling AMPK AChR lipid inhibit lymphoblastic AMP-activated protein kinase EB3D acute tumorigenesis homeostasis dephosphorylation Inhibitor EB 3D leukemia HepG2 inhibitor